← Back
$TSHA All transactions

Taysha Gene Therapies, Inc.

M 10b5-1 Plan

$ Value

$0

Shares

19,021

Price

$0

Filed

Apr 13

Insider

Name

Nagendran Sukumar

Title

President and Head of R&D

CIK

0001665124

Roles

Director Officer

Transaction Details

Transaction Date

2026-04-10

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

455,920

Footnotes

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Filing Info

Accession No.

0001665124-26-000011

Form Type

4

Issuer CIK

0001806310

Nagendran Sukumar's History

Date Ticker Type Value
2026-04-10 TSHA M $33K
2026-04-10 TSHA $892K
2026-04-10 TSHA M $0
2026-01-26 TSHA $124K
2026-01-23 TSHA $423K
2026-01-12 TSHA M $78K
2026-01-12 TSHA M $152K
2026-01-12 TSHA $942K
2026-01-12 TSHA A $0
2026-01-12 TSHA M $0

Other Insiders at TSHA (90d)

Insider Bought Sold Last
Nolan Sean P.
Chief Executive Officer
$840K 2026-01-26
Nagendran Sukumar
President and Head of R&D
$1.4M 2026-04-10
Alam Kamran
CHIEF FINANCIAL OFFICER
$485K 2026-01-26